http://www.advfn.com/nasdaq/rss.asp?symbol=OSIP Osi Pharmaceuticals Company Newsfeed en Tue, 08 Jun 2010 03:42:29 EDT Tue, 08 Jun 2010 03:42:29 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=43131569&headline=astellas-pharma-successfully-completed-tender-offer-for-osi http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=43131569&headline=astellas-pharma-successfully-completed-tender-offer-for-osi <div class='newsbody'><p> TOKYO -(Dow Jones)- Astellas Pharma Inc. (4503.TO) said Tuesday it has successfully completed its $4.0 billion tender offer for OSI Pharmaceuticals Inc. (OSIP), receiving offers for 93% of the U.S. cancer drug-developer's outstanding shares. </p> <p> With over 90% of the shares... Tue, 08 Jun 2010 03:42:29 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=43074919&headline=astellas-pharma-tender-offer-for-osi-successful http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=43074919&headline=astellas-pharma-tender-offer-for-osi-successful <div class='newsbody'><p> TOKYO -(Dow Jones)- Astellas Pharma Inc. (4503.TO) said Thursday it received enough offers of shares in U.S. cancer drug developer OSI Pharmaceuticals Inc. (OSIP) to complete its takeover of the company, a deal that could be worth up to $4.0 billion. </p> <p> The Tokyo-based... Thu, 03 Jun 2010 03:40:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42849929&headline=market-snapshot-u-s-stocks-straddle-flat-line-boosted-by-lowes http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42849929&headline=market-snapshot-u-s-stocks-straddle-flat-line-boosted-by-lowes <div class='newsbody'><p> By Barbara Kollmeyer </p> <p> U.S. stocks bounced between small gains and losses on Monday as earnings from Lowe's and General Motors encouraged investors, but worries persisted over the stability of the euro zone. </p> <p> The Dow Jones Industrial Average (DJI) gained 3 points... Mon, 17 May 2010 10:17:22 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42840151&headline=astellas-agreed-to-buy-osi-pharmaceuticals-for-4-billion http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42840151&headline=astellas-agreed-to-buy-osi-pharmaceuticals-for-4-billion <div class='newsbody'><p> TOKYO -(Dow Jones)- Astellas Pharma Inc. (4503.TO) said Monday it will buy OSI Pharmaceuticals Inc. (OSIP) for $4 billion, bringing an initially hostile takeover attempt to an agreement by raising its original offer price by over 10%. </p> <p> Japan's second largest pharmaceutical... Sun, 16 May 2010 21:13:24 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42582896&headline=roche-diabetes-drug-taspoglutide-shows-promising-test-results http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42582896&headline=roche-diabetes-drug-taspoglutide-shows-promising-test-results <div class='newsbody'><p> By Goran Mijuk </p> <p> Of DOW JONES NEWSWIRES </p> <p> ZURICH -(Dow Jones)- Roche Holding AG (RHHBY) Thursday said its experimental diabetes medicine taspoglutide showed promising results in a late phase test, raising chances the drug could live up to its blockbuster potential... Thu, 29 Apr 2010 05:50:22 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42501298&headline=astellas-extending-tender-offer-for-osi-to-may-17 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42501298&headline=astellas-extending-tender-offer-for-osi-to-may-17 <div class='newsbody'><p> TOKYO -(Dow Jones)- Astellas Pharma Inc. (4503.TO) said Friday it will extend its $3.5 billion tender offer for OSI Pharmaceuticals Inc. (OSIP) by another three weeks to May 17, as OSI's strong share price continues to frustrate its attempts at a takeover. </p> <p> Astellas... Fri, 23 Apr 2010 04:34:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42346473&headline=wellington-management-sells-2-9-million-shares-in-osi-pharma http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42346473&headline=wellington-management-sells-2-9-million-shares-in-osi-pharma <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Mutual fund manager Wellington Management Co. has sold 2.9 million shares of OSI Pharmaceuticals Inc. (OSIP), which is fighting a $3.5 billion hostile takeover attempt from Japanese drug maker Astellas... Mon, 12 Apr 2010 16:47:28 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42309006&headline=och-ziff-reports-5-5-stake-in-osi-pharma http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42309006&headline=och-ziff-reports-5-5-stake-in-osi-pharma <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Och-Ziff Capital Management LLC (OZM) reported a 5.5% stake in OSI Pharmaceuticals Inc. (OSIP), which is fighting a $3.5 billion hostile take-over attempt from Japanese drug maker Astellas Pharma Inc... Thu, 08 Apr 2010 18:20:10 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42196153&headline=astellas-to-extend-osi-tender-offer-through-april-23 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42196153&headline=astellas-to-extend-osi-tender-offer-through-april-23 <div class='newsbody'><p> TOKYO -(Dow Jones)- Astellas Pharma Inc. (4503.TO) said Wednesday it will extend the period of its tender offer for OSI Pharmaceuticals Inc. (OSIP) shares to April 23 from March 31, as its continues to attempt to take over the U.S. cancer drug developer. </p> <p> The Tokyo-based... Wed, 31 Mar 2010 01:02:08 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42052749&headline=astellas-changes-2-nominees-for-election-to-osi-pharma-board http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42052749&headline=astellas-changes-2-nominees-for-election-to-osi-pharma-board <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Japanese drug maker Astellas Pharma Inc. (ALPMY, 4503.TO) changed two director nominations for election to OSI Pharmaceuticals Inc.'s (OSIP) board, a company it is targeting with a $3.5 billion hostile takeover bid. </p> <p> OSI has brushed aside... Fri, 19 Mar 2010 17:09:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42016685&headline=roche-ceo-touts-pipeline-remains-open-to-more-deals http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=42016685&headline=roche-ceo-touts-pipeline-remains-open-to-more-deals <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Roche Holding AG (RHHBY, ROG.VX) Chief Executive Severin Schwan said the integration of its $46.8 billion takeover of Genentech Inc. is "by and large completed," expressed his confidence in the Swiss... Wed, 17 Mar 2010 18:53:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41968620&headline=osi-pharma-rejects-astellas-3-5-billion-takeover-offer http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41968620&headline=osi-pharma-rejects-astellas-3-5-billion-takeover-offer <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> OSI Pharmaceuticals Inc.'s (OSIP) board has rejected Japan drugmaker Astellas Pharma Inc.'s (4503.TO, ALPMY) $3.5 billion takeover bid, saying the $52-a-share price is too low. </p> <p> Shares were up 1% at $58.25 premarket. Astellas' U.S.-traded... Mon, 15 Mar 2010 09:28:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41800531&headline=asia-markets-japanese-drug-makers-put-up-a-fight http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41800531&headline=asia-markets-japanese-drug-makers-put-up-a-fight <div class='newsbody'><p> By Myra P. Saefong </p> <p> Japanese drug makers are facing some stiff competition but they're holding their ground and fighting back as they work to boost overseas deals and raise their share of the generic-drug market. </p> <p> Japanese pharmaceutical firms are "likely to... Tue, 02 Mar 2010 22:45:02 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41795450&headline=correct-astellas-begins-3-5-billion-tender-offer-for-osi-pharma http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41795450&headline=correct-astellas-begins-3-5-billion-tender-offer-for-osi-pharma <div class='newsbody'><p> (Stories at 8:38 a.m. EST and 12:52 p.m. EST referred to the incorrect day in the first paragraph. A corrected version follows.) </p> <pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Astellas Pharma Inc. (ALPMY, 4503.TO) officially launched its... Tue, 02 Mar 2010 14:12:07 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41788603&headline=astellas-begins-3-5-billion-tender-offer-for-osi-pharma http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41788603&headline=astellas-begins-3-5-billion-tender-offer-for-osi-pharma <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Astellas Pharma Inc. (ALPMY, 4503.TO) officially launched its cash tender offer Monday for all shares of OSI Pharmaceuticals Inc. (OSIP) at $52 a share in cash, or $3.5 billion total. </p> <p> The Tokyo-based... Tue, 02 Mar 2010 09:08:10 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41132163&headline=osi-pharma-fda-extends-review-period-for-tarceva-proposal http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=41132163&headline=osi-pharma-fda-extends-review-period-for-tarceva-proposal <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> The Food and Drug Administration has extended the review period for using the cancer drug Tarceva as a first-line treatment in patients with advanced lung cancer, after the agency was given additional data from OSI Pharmaceuticals Inc. (OSIP). </p> <p>... Fri, 15 Jan 2010 13:36:06 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=40792595&headline=fda-panel-rejects-earlier-use-of-tarceva-in-lung-cancer http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=40792595&headline=fda-panel-rejects-earlier-use-of-tarceva-in-lung-cancer <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- A Food and Drug Administration panel Wednesday rejected earlier use of the cancer drug Tarceva in patients with advanced lung cancer. </p> <p> Tarceva, co-marketed by OSI Pharmaceuticals... Wed, 16 Dec 2009 14:55:05 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=40754724&headline=fda-panel-to-consider-wider-use-of-tarceva-in-lung-cancer http://www.advfn.com/nasdaq/StockNews.asp?stocknews=OSIP&article=40754724&headline=fda-panel-to-consider-wider-use-of-tarceva-in-lung-cancer <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- A Food and Drug Administration panel will consider whether the cancer drug Tarceva should be approved for wider use in patients with advanced lung cancer. </p> <p> Tarceva, comarketed by... Mon, 14 Dec 2009 10:55:03 EST